909 Results for https://www.galaxus.ch/en/sector/showdiscussion/hack-someone-snap-visit-kunghaccom-j8f6qlhn-224830
  • Preventing opioid overdoses with naloxone

    As prescription opioid overdoses rise in the U.S., the Prime/MRx Special Investigations Unit (SIU) shares how to identify if someone has overdosed and how you can help save a life

    Prime Article: Perspectives
  • What’s next in the GLP-1 pipeline? Prime’s clinical team shares the latest

    Someone holds a GLP-1 pen needle in their hands.

    PA Sub-Categories: GLP-1 Prime Article: Perspectives
  • Terms of Use

    Effective: January 2021 Terms of use IF YOU ARE EXPERIENCING A MEDICAL EMERGENCY, DIAL 911 AND/OR SEEK IMMEDIATE ATTENTION FROM A HEALTH CARE PROVIDER. THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE....

  • FDA Decisions Expected: March 2026

    Kresladi, by Rocket Pharmaceuticals, is undergoing it’s second review by the FDA for the treatment of severe leukocyte adhesion deficiency type 1 (LAD-1). In June 2024, the FDA issued a CRL for...

  • Prime Careers Spotlight: April 2025

    Principal Financial Systems - Remote Job description: The Process Improvement Project Analyst Principal is responsible for directing a wide variety of initiatives to achieve significant financial,...

  • FDA Decisions Expected: March 2025

    PTC Therapeutics is awaiting the FDA decision for ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The FDA granted ataluren Fast Track and Orphan Drug...

  • FDA Decisions Expected: June 2026

    June 29, 2026: oxylanthanum carbonate Veligrotug is an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody developed by Viridian and submitted to the FDA for the treatment of thyroid eye...

  • FDA Decisions Expected: April 2026

    Polaris is awaiting an FDA decision for pegargiminase, an arginine degrading enzyme, for the treatment of malignant pleural mesothelioma (MPM) with non-epithelioid histology. The FDA granted the...